https://www.nasdaq.com/press-release/aquestive-therapeutics-receives-notification-from-fda-that-it-will-not-be-ready-to
https://www.nasdaq.com/press-release/aquestive-therapeutics-added-to-nasdaq-biotechnology-index-2021-12-17
https://www.nasdaq.com/press-release/aquestive-therapeutics-receives-written-response-to-pre-ind-submission-for-aqst-109
https://www.nasdaq.com/press-release/aquestive-therapeutics-to-participate-in-piper-sandler-33rd-annual-virtual-healthcare
https://www.nasdaq.com/press-release/aquestive-therapeutics-reports-third-quarter-2021-financial-results-provides-business
https://www.nasdaq.com/press-release/aquestive-therapeutics-reports-positive-topline-data-from-phase-1-pharmacokinetic
https://www.nasdaq.com/press-release/aquestive-therapeutics-to-report-third-quarter-2021-financial-results-and-recent
https://www.nasdaq.com/press-release/aquestive-therapeutics-reaches-agreement-to-extend-principal-payments-due-under
https://www.nasdaq.com/press-release/intelgenx-and-aquestive-therapeutics-partner-with-leading-mens-health-company-to
https://www.nasdaq.com/press-release/aquestive-therapeutics-to-participate-in-three-investor-conferences-in-september-2021
https://www.nasdaq.com/press-release/aquestive-therapeutics-negotiates-six-month-extension-to-june-30-2022-for-additional
https://www.nasdaq.com/press-release/aquestive-therapeutics-to-participate-in-12th-annual-wedbush-pacgrow-healthcare
https://www.nasdaq.com/press-release/aquestive-therapeutics-reports-second-quarter-2021-financial-results-provides-0
https://www.nasdaq.com/press-release/aquestive-therapeutics-reports-second-quarter-2021-financial-results-provides
https://www.nasdaq.com/press-release/aquestive-therapeutics-to-report-second-quarter-2021-financial-results-and-recent
https://www.nasdaq.com/press-release/aquestive-therapeutics-announces-fda-acceptance-of-new-drug-application-nda
https://www.nasdaq.com/press-release/aquestive-therapeutics-resubmits-new-drug-application-for-libervanttm-diazepam-buccal
https://www.nasdaq.com/press-release/aquestive-therapeutics-announces-leadership-transition-of-chief-financial-officer
https://www.nasdaq.com/press-release/aquestive-therapeutics-to-participate-in-jmp-securities-and-bmo-capital-market
https://www.nasdaq.com/press-release/aquestive-therapeutics-to-participate-in-2021-rbc-capital-markets-global-healthcare
https://www.nasdaq.com/press-release/aquestive-therapeutics-reports-first-quarter-2021-financial-results-and-provides
https://www.nasdaq.com/press-release/aquestive-therapeutics-to-report-first-quarter-2021-financial-results-and-recent
https://www.nasdaq.com/press-release/aquestive-therapeutics-successfully-demonstrates-repeatable-and-predictable-oral
https://www.nasdaq.com/press-release/aquestive-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results
https://www.nasdaq.com/press-release/aquestive-therapeutics-to-host-investor-analyst-virtual-epinephrine-drug-delivery-rd
https://www.nasdaq.com/press-release/notice-of-lead-plaintiff-deadline-for-shareholders-in-the-aquestive-therapeutics-inc.
https://www.nasdaq.com/press-release/aquestive-therapeutics-reaffirms-near-term-nda-resubmission-for-libervanttm-diazepam
https://www.nasdaq.com/press-release/aquestive-therapeutics-to-announce-fourth-quarter-and-year-end-2020-financial-results
https://www.nasdaq.com/press-release/aquestive-therapeutics-strengthens-board-of-directors-with-appointments-of-julie-krop
https://www.nasdaq.com/press-release/aquestive-therapeutics-appoints-mark-lepore-md-as-chief-medical-officer-for-allergy
https://www.nasdaq.com/press-release/mitsubishi-tanabe-pharma-america-and-aquestive-therapeutics-announce-u.s.-licensing
https://www.nasdaq.com/press-release/aquestive-therapeutics-provides-business-update-2021-01-07
https://www.nasdaq.com/press-release/aquestive-therapeutics-to-present-at-two-upcoming-investor-conferences-2021-01-04
https://www.nasdaq.com/press-release/aquestive-therapeutics-announces-departure-of-chief-financial-officer-and-appointment
https://www.nasdaq.com/press-release/aquestive-therapeutics-to-present-at-piper-sandler-32nd-annual-virtual-healthcare
https://www.nasdaq.com/press-release/aquestive-therapeutics-receives-first-milestone-payment-from-kynmobitm-monetization
https://www.nasdaq.com/press-release/aquestive-therapeutics-completes-fda-type-a-meeting-on-libervant-2020-11-18
https://www.nasdaq.com/press-release/aquestive-therapeutics-reports-third-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/aquestive-therapeutics-signs-royalty-monetization-agreement-with-marathon-asset
https://www.nasdaq.com/press-release/aquestive-therapeutics-to-announce-third-quarter-financial-results-and-recent
https://www.nasdaq.com/press-release/aquestive-therapeutics-receives-complete-response-letter-from-fda-for-libervanttm
https://www.nasdaq.com/press-release/aquestive-therapeutics-initiates-phase-1-pharmacokinetic-trial-of-aqst-108-sublingual
https://www.nasdaq.com/press-release/aquestive-therapeutics-receives-fda-fast-track-designation-for-aqst-108-sublingual
https://www.nasdaq.com/press-release/aquestive-therapeutics-reports-second-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/aquestive-therapeutics-to-present-at-2020-wedbush-pacgrow-healthcare-virtual
https://www.nasdaq.com/press-release/aquestive-therapeutics-to-announce-second-quarter-financial-results-and-recent
https://www.nasdaq.com/press-release/aquestive-therapeutics-files-ind-for-pharmacokinetic-clinical-trials-of-aqst-108
https://www.nasdaq.com/press-release/aquestive-therapeutics-to-present-at-bmo-capital-markets-2020-prescriptions-for
https://www.nasdaq.com/press-release/aquestive-therapeutics-to-hold-virtual-only-annual-meeting-of-stockholders-2020-06-04
https://www.nasdaq.com/press-release/aquestive-therapeutics-advances-royalty-monetization-plan-as-sunovion-pharmaceuticals
https://www.nasdaq.com/press-release/aquestive-therapeutics-to-present-at-2020-rbc-capital-markets-global-healthcare
https://www.nasdaq.com/press-release/aquestive-therapeutics-reports-first-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/aquestive-therapeutics-to-announce-first-quarter-financial-results-and-recent
https://www.nasdaq.com/press-release/aquestive-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results
https://www.nasdaq.com/press-release/aquestive-therapeutics-to-announce-fourth-quarter-and-full-year-2019-financial
https://www.nasdaq.com/press-release/aquestive-therapeutics-announces-u.s.-food-and-drug-administration-filing-acceptance
https://www.nasdaq.com/press-release/aquestive-therapeutics-announces-fda-confirmed-505b2-pathway-for-aqst-108-sublingual
https://www.nasdaq.com/press-release/aquestive-therapeutics-receives-fda-response-to-citizens-petition-2020-01-12
https://www.nasdaq.com/press-release/aquestive-therapeutics-exceeds-top-end-of-guidance-range-for-preliminary-unaudited
https://www.nasdaq.com/press-release/aquestive-therapeutics-announces-pricing-of-public-offering-of-common-stock-2019-12
https://www.nasdaq.com/press-release/aquestive-therapeutics-announces-proposed-public-offering-of-common-stock-2019-12-10
https://www.nasdaq.com/press-release/aquestive-therapeutics-to-host-investor-analyst-libervanttm-diazepam-buccal-film
https://www.nasdaq.com/press-release/aquestive-therapeutics-completes-rolling-submission-of-new-drug-application-nda-to-u
https://www.nasdaq.com/press-release/aquestive-therapeutics-announces-poster-presentations-of-data-on-libervanttm-diazepam
https://www.nasdaq.com/press-release/aquestive-therapeutics-receives-fda-approval-for-exservantm-riluzole-oral-film-2019
https://www.nasdaq.com/press-release/aquestive-therapeutics-licenses-riluzole-oral-film-to-zambon-for-development-and
https://www.nasdaq.com/press-release/aquestive-therapeutics-reports-third-quarter-2019-financial-results-and-raises-2019
https://www.nasdaq.com/press-release/aquestive-therapeutics-reaffirms-full-year-2019-revenue-guidance-and-will-announce
https://www.nasdaq.com/press-release/aquestive-therapeutics-announces-successful-completion-of-phase-1-trial-for-aqst-108
https://www.nasdaq.com/press-release/aquestive-therapeutics-to-announce-second-quarter-2019-financial-results-and-recent
https://www.nasdaq.com/press-release/aquestive-therapeutics-completes-%2470-million-debt-refinancing-2019-07-15
https://www.nasdaq.com/press-release/aquestive-therapeutics-present-two-upcoming-investor-conferences-2019-06-07
